The deal will support up to five R&D programs targeting monthly and quarterly injections, as the drugmaker looks to extend the reach of its GLP-1 blockbusters for obesity, type 2 diabetes and cardiometabolic conditions.
An initial €615 million euros will cover an upfront payment plus certain regulatory milestones, with the remaining payout tied to revenues. Additionally, Nanexa will have the opportunity to collect single-digit royalties on future global net sales.
Novo plans to employ the company’s PharmaShell technology to offer controlled-release doses through a self-administered injector. Nanexa’s approach encapsulates the active pharmaceutical ingredient with a dense, inorganic coating, applied through a gas-phase process similar to semiconductor manufacturing known as atomic layer deposition. This forms a depot for the drug at the injection site that dissolves over time.
